Call Now ...

Take my picture, not of my insides?

Aug 17th, 2010 | By | Category: Medical

PillCam™ ESO 2

Creighton University Medical Center states it is the first institution in Omaha to offer PillCam ESO 2, a camera-in-a-pill that allows doctors to evaluate and diagnose diseases of the esophagus including gastroesophageal reflux disease (GERD) and Barrett’s esophagus, a pre-cancerous condition. The latest camera The PillCam ESO 2 is a smooth plastic capsule with two tiny cameras, one at each end, capable of taking approximately 3,343 pictures (18 per second) of the esophagus. Images are transmitted from the PillCam ESO to a recording device. Less than 30 minutes, physicians have enough images to determine a diagnosis.

Image: property of Creighton University

PillCam ESO 2 is an alternative to traditional endoscopy, the most common procedure for examining the esophagus. Rather than advancing a long scope (endoscope) into the mouth and down the throat to the esophagus, many patients now only swallow a pill in the doctor’s office. The pill is the size of a large vitamin (11mm x 26mm. • Weight- 3.7 grams).  

PillCam ESO 2 features include:

  • Improved image quality
  • A 21% increase in the angle of view over PillCam ESO 2 providing physicians more than a 100 percent increase in mucosal tissue coverage
  • Added Automatic Light Control (ALC) to provide optimal illumination for each image
  • Increased capture rate of 18 frames per second (fps), capturing 30% more images
  • Up to 30 minutes operating time
  • Same dimensions as PillCam ESO 2

 Diseases that PillCam™ ESO diagnose:

  • Gastroesophageal Reflux Disease (GERD) occurs when the lower esophageal sphincter (LES) muscle malfunctions or does not close properly and stomach acid leaks back into the esophagus, causing a burning sensation in the chest or throat. Anyone experiencing heartburn twice a week or more may have GERD.
  • Barrett’s Esophagus is a condition resulting from prolonged gastroesophageal reflux disease and is a risk factor for esophageal cancer.
  • Esophagitis is inflammation of the esophagus.

PillCam™ ESO Procedure:

  • The patient fasts for two hours before swallowing the PillCam™ ESO.
  • The PillCam™ ESO 2 is swallowed with water while the patient lies on his or her back.
  • After swallowing the PillCam™ ESO 2, the patient is raised by 30-degree angles every two minutes over a six-minute ingestion period until he or she is sitting upright.
  • The PillCam™ ESO makes its way through the esophagus in about three minutes.
  • The images are transmitted to a recorder belt worn around the patient’s waist.
  • The total procedure takes approximately 20 minutes.
  • PillCam™ ESO 2 is disposable and passes through the gastrointestinal (GI) tract naturally and painlessly, usually within 24 to 72 hours.

The PillCam™ ESO 2  is not appropriate for people with swallowing disorders or with known or suspected gastrointestinal obstructions, strictures or fistulas. People with cardiac pacemakers or other implanted electromedical devices should not use the PillCam™ ESO 2.

Parent Company: Elron Electronic Industries Ltd.  (ELRN) Pink Sheets: ELRNF

Given Imaging Ltd. Type Public (NASDAQ: GIVN)
Industry medical technology
Founded 1998
Headquarters  Yoqneam, Israel
Key people Homi Shamir, CEO
Products capsule endoscopy
Revenue ▲ US$ 141.76 million (2009)
Operating income ▲ US$ 10.32 million (2009)
Net income ▲ US$ 14.34 million (2009)
Employees 400
Website www.givenimaging.com

References and Credits: Creighton University

Comments are closed.